Insulin therapy and its shortcomings - The need for new approaches

Diabetic Medicine

Volumn 14, Issue SUPPL. 2, 1997, Pages

  Whitehouse, F W ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Chronic hyperglycaemia; Diabetes mellitus; Glycaemic control; Insulin Amylin

Indexed keywords

AMYLIN;

ARTICLE; CHRONIC DISEASE; DIABETES CONTROL; HORMONAL REGULATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; SUBSTITUTION THERAPY;

EID: 0030845574     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1096-9136(199706)14:2+3.3.co;2-j     Document Type: Article

References (29)

1. Joslin EP. The Treatment of Diabetes Mellitus (first edition). Philadelphia: Lea & Febiger, 1916.
2. Banting FG, Best CH. The internal secretion of the pancreas. J Lab Clin Med 1922; 7: 251-266.
3. Banting FG, Best CH, Collip JB, et al. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 1922; 12: 141-146.
4. Beetham WP. Visual prognosis of proliferating diabetic retinopathy. Br J Ophthalmol 1963; 47: 611-619.
5. Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol 1936; 12: 83-97.
6. Jordan WR. Neuritic manifestations in diabetes mellitus. Arch Intern Med 1936; 57: 307-366.
7. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
8. Diabetes Control and Complications Trial Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18: 1415-1427.
9. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycaemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 1996; 19: 324-327.
10. Gulan M, Pearlman K, Sele M, Albisser AM, Zinman B. Counterregulatory hormone responses preserved after long-term intravenous insulin compared to subcutaneous insulin infusion. Diabetes 1988; 37: 526-531.
11. Lassmann-Vague V, Belicar P, Alessis C, Raccah D, Vialettes B, Vague P. Insulin kinetics in Type 1 diabetic patients treated by continuous intraperitoneal insulin infusion: influence of anti-insulin antibodies. Diabetic Med 1996; 13: 1051-1055.
12. Nathan DM, Dunn FL, Bruch J, et al. Post-prandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients. Am J Med 1996; 100: 412-417.
13. Howard BV, Lee ET, Fabsitz RR, et al. Diabetes and coronary heart disease in American Indians. The Strong Heart Study. Diabetes 1996; 45 (suppl 3): S6-S13.
14. Ronnemaa T, Laasko M, Pyörälä K, et al. High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and non-diabetic subjects. Arterioscler Thromb 1991; 11: 80-90.
15. Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death, and complications. Diabetologia 1978; 14: 363-370.
16. Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. II. Factors influencing the prognosis. Diabetologia 1978; 14: 371-377.
17. Genuth S. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. Ann Int Med 1996; 124: 104-109.
18. Simpson HCR, Simpson RW, Lousley S, et al. A high carbohydrate leguminous fibre diet improves all aspects of diabetic control. Lancet 1981; 1: 1-5.
19. Geekie MA, Porteous J, Hockaday TD, et al. Acceptability of high-fibre diets in diabetic patients. Diabet Med 1986; 3: 52-55.
20. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Multicenter, controlled clinical trial. Ann Int Med 1994; 121: 928-935.
21. Garg SK, Carmain JA, Braddy KC. Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with Type I diabetes. Diabet Med 1996; 13: 47-52.
22. Heinemann L, Heise T, Wahl LCh. Prandial glycaemia after a carbohydrate-rich meal in Type I diabetic patients: using the rapid-acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med 1996; 13: 625-629.
23. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreas of type 2 diabetic patients. Proc Natl Acad Sci USA 1987; 84: 8628-8632.
24. Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG. Amylin concentrations and glucose control. Lancet 1992; 339: 1179-1180.
25. Westermark P, Wilander E, Westermark GT, Johnson KH. Islet amyloid polypeptide-like immunoreactivity in the islet B cells of type 2 (non-insulin-dependent) diabetic and non-diabetic individuals. Diabetologia 1987; 30: 887-892.
26. Ludvik B, Lell B, Hartter E, Schnack C, Prager R. Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes 1991; 40: 1615-1619.
27. Koda JE, Fineman MS, Kolterman OC, Caro JF. 24 hour plasma amylin profiles are elevated in IGT subjects vs normal controls. Diabetes 1995; 44 (suppl 1): 238A.
28. Leighton B, Cooper GJ. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 1988; 335: 632-635.
29. Silvestre RA, Peiro E, Degano P, Miralles P, Marco J. Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas. Regul Pept 1990; 31: 23-31.